Literature DB >> 15740718

A "locked-on," constitutively active mutant of the adenosine A1 receptor.

Rianne A F de Ligt1, Scott A Rivkees, Anna Lorenzen, Rob Leurs, Ad P IJzerman.   

Abstract

We studied the wild-type human adenosine A1 receptor and three mutant receptors, in which the glycine at position 14 had been changed into an alanine, a leucine, or a threonine residue. All receptors were characterized in radioligand binding experiments, the wild-type and the Gly14Thr mutant receptor in greater detail. Both receptors were allosterically modulated by sodium ions and PD81,723 (2-amino-4,5-dimethyl-3-thienyl-[3(trifluoromethyl)-phenyl]methanone), although in a different way. All mutant receptors appeared to be spontaneously or "constitutively" active in a [35S]GTPgammaS binding assay, the first demonstration of the existence of such CAM (constitutively active mutant) receptors for the adenosine A1 receptor. The Gly14Thr mutant receptor was also constitutively active in another functional assay, i.e., the inhibition of forskolin-induced cAMP production in intact cells. Importantly, this mutant displayed a peculiar "locked-on" phenotype, i.e., neither agonist nor inverse agonist was capable of modulating the basal activity in both the GTPgammaS and the cAMP assay, unlike the wild-type and the two other mutant receptors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15740718     DOI: 10.1016/j.ejphar.2005.01.007

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

Review 1.  International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update.

Authors:  Bertil B Fredholm; Adriaan P IJzerman; Kenneth A Jacobson; Joel Linden; Christa E Müller
Journal:  Pharmacol Rev       Date:  2011-02-08       Impact factor: 25.468

2.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 3.  Allosteric modulation of purine and pyrimidine receptors.

Authors:  Kenneth A Jacobson; Zhan-Guo Gao; Anikó Göblyös; Adriaan P Ijzerman
Journal:  Adv Pharmacol       Date:  2011

4.  Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis.

Authors:  Johannes R Hov; Verena Keitel; Jon K Laerdahl; Lina Spomer; Eva Ellinghaus; Abdou ElSharawy; Espen Melum; Kirsten M Boberg; Thomas Manke; Tobias Balschun; Christoph Schramm; Annika Bergquist; Tobias Weismüller; Daniel Gotthardt; Christian Rust; Liesbet Henckaerts; Clive M Onnie; Rinse K Weersma; Martina Sterneck; Andreas Teufel; Heiko Runz; Adolf Stiehl; Cyriel Y Ponsioen; Cisca Wijmenga; Morten H Vatn; Pieter C F Stokkers; Severine Vermeire; Christopher G Mathew; Benedicte A Lie; Ulrich Beuers; Michael P Manns; Stefan Schreiber; Erik Schrumpf; Dieter Häussinger; Andre Franke; Tom H Karlsen
Journal:  PLoS One       Date:  2010-08-25       Impact factor: 3.240

5.  Determination of adenosine A1 receptor agonist and antagonist pharmacology using Saccharomyces cerevisiae: implications for ligand screening and functional selectivity.

Authors:  Gregory D Stewart; Celine Valant; Simon J Dowell; Dalibor Mijaljica; Rodney J Devenish; Peter J Scammells; Patrick M Sexton; Arthur Christopoulos
Journal:  J Pharmacol Exp Ther       Date:  2009-07-29       Impact factor: 4.030

6.  Cancer-Related Somatic Mutations in Transmembrane Helices Alter Adenosine A1 Receptor Pharmacology.

Authors:  Xuesong Wang; Willem Jespers; Kim A N Wolff; Jill Buytelaar; Adriaan P IJzerman; Gerard J P van Westen; Laura H Heitman
Journal:  Molecules       Date:  2022-06-10       Impact factor: 4.927

7.  Allosteric modulation of adenosine receptors.

Authors:  Anikó Göblyös; Ad P Ijzerman
Journal:  Purinergic Signal       Date:  2008-07-10       Impact factor: 3.765

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.